The mortality benefit seen with the newer more potent oral P2Y12 inhibitors prasugrel and ticagrelor over clopidogrel is dependent on the underlying risk: A class effect as suggested by a meta-regression analysis
Keywords: P2Y12 inhibitor; Prasugrel; Ticagrelor; Acute coronary syndrome (ACS); Meta-regression; Mortality;